Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: substance-related disorder therapeutics - Biotie/Roche

Drug Profile

Research programme: substance-related disorder therapeutics - Biotie/Roche

Alternative Names: SYN-119

Latest Information Update: 29 Mar 2011

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Synosia Therapeutics
  • Class
  • Mechanism of Action Metabotropic glutamate receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Substance-related disorders

Most Recent Events

  • 01 Feb 2011 Synosia Therapeutics has been acquired by Biotie Therapies Corp.
  • 12 Mar 2009 Preclinical development is ongoing for Drug abuse
  • 10 Mar 2009 Synosia Therapeutics and Roche have modified the terms of their original agreement for development of certain drugs for CNS disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top